• Taux USA 10Y +1,82 %
  • Taux FR 10Y +-0,05 %
Matières premières
  • Pétrole WTI56,55 $
  • Cours Or 1486,05 $
Forex
  • Bitcoin 9322,67 $
  • Eur/Usd 1,11
Chiffres clés - Inflation
  • Europe +1.70 % / an
  • France +1.20 % / an
Chiffres clés
  • PIB Europe +1.50 % / an
  • PIB France +0.90 % / an
Accueil » Bourse de Paris » Communiqués
line
line

Frost & sullivan : l'industrie pharmaceutique affronte de multiples d?fis; son avenir r?side dans la p?rennit? de nouvelles lignes de produits

Catégorie : ,

Source : Hugin Posté dans la rubrique le 13/06/2005 à  14:57


FROST & SULLIVAN : L'industrie pharmaceutique affronte de multiples d?fis; son avenir r?side dans la p?rennit? de nouvelles lignes de produits

Presse économique/Presse médicale

LONDON--(BUSINESS WIRE)--June 13, 2005—Les coûts élevés de développements cliniques alliés au déclin du taux de succès des découvertes de médicaments font chuter les niveaux de productivité de l'industrie pharmaceutique au niveau mondial. La prochaine expiration des brevets de plusieurs médicaments phares ainsi que l'émergence relative de solutions génériques alternatives ne fait qu'exacerber la situation.

Pharmaceutical Industry Faces Multiple Challenges; Future Lies in Drug Pipeline Sustainability

Business Editors/Health/Medical Writers

LONDON--(BUSINESS WIRE)--June 13, 2005--High clinical development costs coupled with declining drug discovery success rates are causing productivity levels to fall in the global pharmaceuticals industry

The imminent patent expiry of several major blockbuster drugs and the related rise of cheaper generic alternatives is further exacerbating the situation.

Despite this, the global pharmaceutical industry offers significant growth opportunity for participants that can build new strategic business models

Estimated at USD 554.00 billion in 2004, the global pharmaceuticals market is forecast to register an annual growth rate of 8.2 per cent from 2004 to 2011 to reach USD 967.00 billion.

Such expansion is expected, however, to be based on the ability of pharmaceuticals companies to adapt to changes in patient population, and target diseases of unmet medical need to maximise revenue potential

For instance, an aging global population is poised to drive pharmaceutical drugs for indications such as macular degeneration and Alzheimer's disease.

Drugs that address rising multifactorial disorders such as cancer as well as lifestyle disorders such as obesity are also likely to experience strong revenue growth

Moreover, as patient groups become more fragmented and diagnostic methods improve, the demand for evidence-based personalised treatments is likely to increase

"It is essential for major pharmaceuticals companies to move from the blockbuster model and adopt new strategies that cater to specific diseases areas and populations," notes Frost & Sullivan (http://healthcare.frost.com) Healthcare Analyst Phil Webster.

"To grow in this new era of evidence-based personalised medicine, companies should generate a sustainable product pipeline characterised by improved productivity and diversity." Market participants need to replace their dependence on a limited number of highly lucrative drug candidates with a more comprehensive and diverse product portfolio.

Innovative products that focus on areas of unmet medical need and cover a broad range of disease indications are likely to underpin a strong, sustainable product pipeline

Furthermore, companies need to examine reformulations and investigate new indications for existing blockbuster drugs

At the same time, the use of computer modelling and biomarker discovery to aid the discovery of promising drug candidates is likely to facilitate an enhanced understanding of the clinical development process and help them to make more informed investment decisions

"Less investment will be lost through late stage drug candidate failures as more compounds succeed in the clinical development process," elaborates Mr. Webster.

"More novel techniques to identify toxic or ineffective drugs early in the development process such as the use of biological models, bioinformatics and biomarkers will drive down development costs, increase revenues and improve overall industry productivity." As large pharmaceuticals companies try to enhance their drug development pipelines, mergers, acquisitions and licensing agreements for individual compounds are likely to gain appeal

.

Mergers and strategic collaborations to invest in existing leads are also likely to diffuse the cost of potential failures, thereby preventing the draining of company resources

If you are interested in an analysis overview providing an introduction into the World Clinical Development Pipelines in the Pharmaceuticals Industry - then send an email to Katja Feick -Corporate Communications at katja.feick@frost.com with the following information: Full name, Company Name, Title, Contact Tel Number, Email.

Upon receipt of the above information, an overview will be emailed to you

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years.

The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities

Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

For more information, visit http://www.frost.com

World Clinical Development Pipelines in the Pharmaceuticals Industry

F238-52

List of keywords in this press release: clinical development, pharmaceuticals industry, sustainable drug pipelines, drug discovery, patent expiry, blockbuster drugs, macular degeneration, Alzheimer's disease, cancer, obesity, evidence-based treatments, personalised medicine, drug candidates, computer modelling, molecular biomarking, biological models, bioinformatics, biomarkers, high throughput screening, gene therapy, generics, generic pharmaceuticals, broad-spectrum antibiotics List of key industry participants: Pfizer Inc., Johnson & Johnson Inc., Astra-Zeneca Plc, Roche Molecular Systems, Bayer Diagnostics, Bristol Myers-Squibb, Cirion Biopharma Research Inc, Life Sciences Research Inc, MDS Pharma Services, aai Development Inc, Inc, Vivometrics Inc, Omnicare Inc, Parexel International, ABC R.O., Evidence Clinical and Pharmaceutical Research, www.clinicalresearch.de, CTS Europe, Clinical Trial Operations (CTO) B.V., Aster Cephac Group, Biotrial S.A., IFE Baltic, INC Research Europe

CONTACT:

Frost & Sullivan Europe:

Katja Feick, +44 (0) 20 7915 7856 fax: +44 (0) 20 7730 3343

katja.feick@frost.com

or Americas: Danielle White, 210-247-2403 fax: 210-348-1003

dwhite@frost.com

or Apac: Radhika Menon Theodore, +91 44 24314263 Ext: 312

rmtheodore@frost.com

or India: Surbhi Dedhia, +91 22 2832 4705 Ext: 131

sdedhia@frost.com

http://www.frost.com




share
pin it


A VOIR AUSSI
Commentaires

0 commentaires
Ajouter votre commentaire !
Pour réagir à cette info : Connectez-vous à votre espace membre
Ajouter le smiley Sourire  Ajouter le smiley Rigole  Ajouter le smiley Tire la langue  Ajouter le smiley Clin d'oeil  Ajouter le smiley En colère !  Ajouter le smiley Embarrassé  Ajouter le smiley Choqué  Ajouter le smiley Star  Ajouter le smiley Triste
Vous devez être membre de leguideboursier.com pour ajouter votre commentaire. Cliquez-ici pour devenir membre !

Conditions d'utilisation
Les commentaires sont envoyés par les internautes et ne sont pas rédigés par notre rédaction.
Notre rédaction se réserve le droit de supprimer les commentaires ne respectant pas notre charte éditoriale.
Il est interdit d'écrire des commentaires contraires aux lois françaises.
Le commentaire une fois diffusé ne peut etre supprimé ou modifié qu'en envoyant un email
Mentions légales

Ce contenu est diffusé par Hugin, il n`a qu`une portée informative et pédagogique.
Les informations et données financières ainsi que les analyses diffusées par Hugin n`ont aucune valeur contractuelle et ne constituent en aucun cas une aide à la décision, une offre de vente ou une sollicitation d`achat de valeurs mobilières ou d`instruments financiers.
La responsabilité de LeGuideBoursier.com et/ou de ses dirigeants et salariés ne peut être retenue directement ou indirectement suite à l`utilisation des informations et analyses par les lecteurs et sur la pertinence des informations diffusées.
Il est recommandé à toute personne non avertie de consulter un conseiller professionnel avant tout investissement, car le trading peut vous exposer à des pertes supérieures aux dépôts chez votre broker.
Tout investisseur doit se faire son propre jugement avant d`investir dans un produit financier afin qu`il soit adapté à sa situation financière, fiscale et légale.
Contenu proposé par Le guide boursier : D'autres articles qui pourraient vous intérresser
-